JP2003306432A - Prophylactic or therapeutic agent for renal disease - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a prophylactic or a therapeutic agent for diabetic nephropathy or glomerulonephritis. <P>SOLUTION: The prophylactic or therapeutic agent for the renal diseases comprises a compound represented by general formula (I) [wherein, R<SP>1</SP>denotes hydrogen or a hydrocarbon residue which may be substituted; R<SP>2</SP>denotes a carboxy group which may be esterified; R<SP>3</SP>denotes a group forming an anion or a group convertible thereinto; X indicates that a phenylene group is bound directly or through a spacer having ≥2 atomic chains to a phenyl group; n denotes an integer of 1 or 2; ring A denotes a benzene ring which may have a substituent other than the group represented by R<SP>2</SP>; Y denotes a direct bond, O, S(O)<SB>m</SB>(wherein, m denotes 0, 1 or 2) or N(R<SP>4</SP>) (wherein, R<SP>4</SP>denotes hydrogen or an alkyl group which may be substituted)] or its salt as an active ingredient. <P>COPYRIGHT: (C)2004,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to angiotensin.
The present invention relates to a preventive or therapeutic agent for diabetic nephropathy or glomerulonephritis, which comprises a compound having an II antagonistic action or a salt thereof as an active ingredient.

[0002]

2. Description of the Related Art The kidney is one of the main target organs of hypertension, and persistent hypertension leads to various renal disorders mainly through renal vascular lesions. And renal spasm and degenerative lesions of elastic fibers lead to higher blood pressure. It is believed that hypertension increases renal intraglomerular pressure, which overloads the glomerulus, which stimulates fibrosis and expansion of the mesangial region, leading to glomerulosclerosis.
Also in diabetic nephropathy, microalbuminuria occurs following an increase in renal glomerular pressure, and when it progresses further, glomerulosclerosis is caused, renal function declines, chronic renal failure occurs, and treatment with artificial dialysis occurs. Is required. Currently, more than 20% of patients who have end-stage renal failure and start dialysis therapy
Is due to diabetic nephropathy. The number of artificial dialysis patients is increasing as the years progress, and it is becoming a major medical problem. At present, there is no complete drug treatment for this chronic renal failure. It is said that lowering blood pressure by antihypertensive treatment does not always improve renal failure, but may worsen it.

Compounds having angiotensin II antagonism are known as therapeutic agents for cardiovascular diseases such as hypertension, heart disease (cardiac hypertrophy, heart failure, myocardial infarction, etc.), stroke, nephritis, etc. (JP-A-4-364171). , Etc.), and its mechanism of action is believed to be due to inhibition of binding of angiotensin II, which has a strong vasoconstrictor action, to the angiotensin II receptor. European Patent Publication EP0459136A _1, is described that the angiotensin II antagonist can be used in the treatment of nephropathy or nephritis. Regarding the relationship between renal disease and hypertension, many results have been reported both clinically and experimentally.
It is now well known that the kidney is directly or indirectly involved in the cause of hypertension, and conversely is an organ susceptible to hypertension. However, with regard to the hypertension of chronic glomerulonephritis, which is the most frequent secondary hypertension, unclear points remain such as the cause of hypertension, the effect on the course of nephritis, and the effect of antihypertensive treatment on the prognosis. At present, nephritis has been considered as a clinical concept that is found in some diseases of different origins. With the spread of renal biopsy, renal diseases have been reviewed and the concept of a disease with proteinuria has been widely introduced (Shibata and Nephrology Seiichi Shibata Bunkodo (1988)). What has been conventionally considered as one of glomerulonephritis is glomerulonephritis, chronic pyelonephritis, IgA nephropathy, periarteritis nodosa, gout, diabetes, systemic lupus erythematosus (S
LE), cirrhosis, hereditary renal disease, amyloidosis,
Differentiated by Wegener's granulomatosis. The diabetic complication of hypertensive patients promotes cardiovascular damage and organ complications, and has a great influence on life prognosis and the like. Therefore, in the treatment, it is important to control blood pressure within a normal range while paying attention to diabetes management and improvement or prevention of arteriosclerosis.

[0004]

DISCLOSURE OF THE INVENTION The present invention provides a drug useful for the prevention or treatment of diabetic nephropathy or glomerulonephritis.

[0005]

[Means for Solving the Problems] In view of the above-mentioned circumstances, the present inventors have earnestly studied a drug for preventing or treating nephropathy or nephritis, and as a result, an angiotensin II antagonist represented by a specific structural formula. The present invention was completed by finding that a compound having an action is extremely effective in preventing or treating diabetic nephropathy or glomerulonephritis.

That is, the present invention provides (1) general formula (I)

[Chemical 4] (In the formula, R ¹ represents hydrogen or an optionally substituted hydrocarbon residue, R ² represents an optionally esterified carboxyl group, and R ³ is a group capable of forming an anion or a substituent thereof. Represents a group to be obtained, X represents that the phenylene group and the phenyl group are bonded directly or through a spacer having an atomic chain of 2 or less, and n represents an integer of 1 or 2,
Ring A represents a benzene ring which may have a substituent in addition to the group represented by R ² , and Y represents a bond, —O—, —
S (O) m- (in the formula, m represents 0, 1 or 2) or -N (R ⁴ )-(in the formula, R ⁴ represents hydrogen or an optionally substituted alkyl group) ) Is a preventive or therapeutic agent for diabetic nephropathy or glomerulonephritis, which comprises a compound represented by the formula (4) or a salt thereof as an active ingredient. The compound used for the prophylactic or therapeutic agent of the present invention has the general formula (I) above.
As represented by the formula (1), the most important structural feature thereof is that R ² has a carboxyl group which may be esterified, and R ³ has a group capable of forming an anion or a group capable of changing it. Especially. By having such a structure, an extremely strong preventive or therapeutic effect for diabetic nephropathy or glomerulonephritis is exerted.

The compound represented by the general formula (I) having angiotensin II antagonism in the present invention can be advantageously used for prevention or treatment of diabetic nephropathy or glomerulonephritis. Examples of the hydrocarbon residue as R ¹ include an alkyl group, an alkenyl group, an alkynyl group,
Examples thereof include a cycloalkyl group, an aryl group and an aralkyl group, and among them, an alkyl group, an alkenyl group and a cycloalkyl group are preferable. The alkyl group as R ¹ is a lower alkyl group having about 1 to 8 carbon atoms, which may be linear or branched and includes, for example, methyl, ethyl, propyl,
Isopropyl, butyl, isobutyl, sec-butyl, t
-Butyl, pentyl, i-pentyl, hexyl, heptyl, octyl and the like. The alkenyl group as R ¹ is a lower alkenyl group having about 2 to 8 carbon atoms and may be linear or branched, and examples thereof include vinyl, propenyl, 2-butenyl, 3-butenyl, isobutenyl,
2-octenyl and the like can be mentioned. The alkynyl group as R ¹ is a lower alkynyl group having about 2 to 8 carbon atoms, which may be linear or branched and includes, for example, ethynyl,
2-propynyl, 2-butynyl, 2-pentynyl, 2-
Examples include octynyl. Examples of the cycloalkyl group as R ¹ include lower cycloalkyl having about 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl,
Examples include cyclopentyl and cyclohexyl. The above-mentioned alkyl group, alkenyl group, alkynyl group or cycloalkyl group is a hydroxyl group or an optionally substituted amino group (eg, amino, N-lower (C _1-4 ) alkylamino, N, N-dilower (C _1-4 ) Alkylamino etc.), halogen, lower (C _1-4 ) alkoxy group, lower (C _1-4 ) alkylthio group and the like. The aralkyl group as R ¹ is, for example, phenyl-lower (C _1-4 ) alkyl such as benzyl and phenethyl, and the aryl group as R ¹ is, for example, phenyl.

The above-mentioned aralkyl group or aryl group is
At any position on the benzene ring, for example halogen
(Eg, F, Cl, Br, etc.), nitro, substituted
Amino group (eg, amino, N-lower (C_1-4) Al
Kiramino, N, N-di-lower (C_{1- Four}) Alkylamino
Do), low grade (C_1-4) Alkoxy (eg methoxy, eth
Kish, etc.), low grade (C_1-4) Alkylthio (eg, methyl
Thio, ethylthio, etc.), lower (C_1-4) Alkyl
(Eg, methyl, ethyl, etc.) and the like.
Among the above, R¹May be substituted as
Alkyl, alkenyl or cycloalkyl groups (eg,
Hydroxyl group, amino group, halogen or lower (C _1-4)
Lower optionally substituted by a lucoxy group (C_1-5) Al
Kill, low grade (C_{2- Five}) Alkenyl group or lower (C_3-6)
Cycloalkyl groups) are preferred. Y is a bond,-
O-, -S (O) m- (in the formula, m represents 0, 1 or 2)
) Or -N (R^Four)-(R^FourIs hydrogen or substituted
Represents an optionally lower alkyl), preferably
Joint, -O-, -S- or -N (R^Four)-(R^FourIs hydrogen
Or low (C_1-4) Alkyl (eg, methyl, ethyl, propyl
Ropil, isopropyl, butyl, sec-butyl, t-butyl
Etc.)).

In the above general formula (I), the group capable of forming an anion as R ³ (group having a hydrogen atom capable of being released as a proton) or a group capable of being converted into it is:
A 5- to 7-membered (preferably 5 to 6-membered) monocyclic optionally substituted heterocyclic residue containing one or more of N, S, and O as shown below (preferably , A nitrogen-containing heterocyclic residue having a hydrogen atom capable of being deprotonated) or a group capable of being converted into it in vivo. For example,

[0010]

[Chemical 5] And the bond between the group represented by the formula R ³ and the phenyl group to which the group is bonded is carbon-carbon as shown above.
Not only a carbon bond, but when g = -NH- is shown in the above formula, it may be bonded through one of a plurality of nitrogen atoms. For example,

[0011]

[Chemical 6]

[Chemical 7] > = Z,> = Z ′ and> = Z ″ are each a carbonyl group, a thiocarbonyl group or an optionally oxidized sulfur atom (eg, S, S (O), S (O) ₂ etc.) (preferably Represents a carbonyl or thiocarbonyl group, more preferably a carbonyl group), m represents 0, 1 or 2, and R
⁷ represents a hydrogen atom or an optionally substituted lower alkyl group (eg, lower (C _1-4 ) alkyl such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl). ]

R ³ is, for example, 2,5-dihydro-5
-Oxo-1,2,4-oxadiazole ring residue, 2,5
-Dihydro-5-thioxo-1,2,4-oxadiazole ring residue or 2,5-dihydro-5-oxo-1,2,
A group having simultaneously a —NH or —OH group as a proton donor such as a 4-thiadiazole ring residue and a carbonyl group, a thiocarbonyl group or a sulfinyl group as a proton acceptor is preferable. Further, the heterocyclic residue represented by R ³ may have a substituent on the ring bonded to form a condensed ring, and R ³ is a 5- or 6-membered heterocyclic ring. Residues are preferred. R ³ is especially a formula

[Chemical 8] [In formula, i shows -O- or -S-, j is> C =
0,> C = S or> S (O) _m , where m is as defined above. ] A group represented by (in particular, 2,5-dihydro-5
-Oxo-1,2,4-oxadiazol-3-yl,
2,5-dihydro-5-thioxo-1,2,4-oxadiazol-3-yl, 2,5-dihydro-5-oxo-
1,2,4-thiadiazol-3-yl) is preferred. R
The substitution position of ³ may be any of the ortho, meta and para positions, but the ortho position is preferred.

Further, the above heterocyclic residue (R ³ ) has tautomers as shown below. For example,

[Chemical 9] There are three tautomers of a, b and c such as

[Chemical 10] The heterocyclic residue represented by includes all of the above a, b and c. Further, as R ³ , a carboxyl group, a tetrazolyl group, a trifluoromethanesulfonic acid amide group (-NHSO ₂ CF ₃ ), a phosphoric acid group, a sulfonic acid group, a cyano group, a lower (C _1-4 ) alkoxycarbonyl group, etc. Of course, these groups may be protected by a lower alkyl group which may be substituted or an acyl group and the like, and may be protected under biological or physiological conditions (for example, oxidation, reduction or hydrolysis by in vivo enzymes, etc.). In vivo reaction) or a group capable of chemically forming an anion or a group capable of being converted into an anion.

R ³ is optionally substituted lower (C _1-4 ) alkyl (eg, methyl, triphenylmethyl, methoxymethyl, ethoxymethyl, p-methoxybenzyl, p-nitrobenzyl, etc.) or acyl Groups (eg lower (C _2-5 ) alkanoyl, benzoyl etc.)
A tetrazolyl or a carboxyl group (preferably tetrazolyl) which may be protected with is preferable. R ³
The substitution position of may be any of the ortho, meta and para positions, but of these, the ortho position is preferred. X represents that adjacent phenylene groups and phenyl groups are bonded directly or preferably through a spacer having an atomic chain of 2 or less (preferably direct bonding), and the spacer having an atomic chain of 2 or less constitutes a straight chain portion. Any divalent chain having 1 or 2 atoms may be used and may have a side chain. Specifically, lower (C _1-4 ) alkylene, -CO-,
-O-, -S-, -NH-, -CO-NH-, -OC
_{H 2 -, - S-CH} 2 -, - CH = CH- , and the like. n represents an integer of 1 or 2 (preferably 1).

The above formulas represented by R ³ , X and n

[Chemical 11] as

[Chemical 12] What is represented by is preferable.

In the general formula (I), the optionally esterified carboxyl group as R ² has, for example, the formula:
CO-D [in the formula, D is a hydroxyl group or an optionally substituted alkoxy group (eg, an alkyl group is a hydroxyl group, optionally substituted amino (eg, amino, dimethylamino, diethylamino, piperidino, morpholino, etc.), halogen) , Lower (C _1-6 ) alkoxy, lower (C _1-6 ) alkylthio or optionally substituted dioxolenyl
(Eg, 5-methyl-2-oxo-1,3-dioxolen-4-yl, etc.), a lower (C _1-6 ) alkoxy group which may be substituted, or a formula —O—CH (R ⁶ ) —
OCOR ⁵ [wherein, R ⁶ is hydrogen, a linear or branched lower alkyl group having 1 to 6 carbon atoms (eg, methyl, ethyl, n
-Propyl, isopropyl, n-butyl, isobutyl, t
-Butyl, n-pentyl, isopentyl, neopentyl, etc.), a straight-chain or branched lower alkenyl group having 2 to 6 carbon atoms or a cycloalkyl group having 3 to 8 carbon atoms (eg,
Cyclopentyl, cyclohexyl, cycloheptyl, etc., and R ⁵ is a linear or branched lower alkyl group having 1 to 6 carbon atoms (eg, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec. -Butyl, t-butyl, n-pentyl, isopentyl, neopentyl, etc.), a straight-chain or branched lower alkenyl group having 2 to 6 carbon atoms (eg, vinyl, allyl, butenyl, i-butenyl, 2-hexenyl, etc.) ), A cycloalkyl group having 3 to 8 carbon atoms (eg, cyclopentyl, cyclohexyl, cycloheptyl, etc.), a cycloalkyl group having 3 to 8 carbon atoms (eg, cyclopentyl, cyclohexyl, cycloheptyl, etc.) or may be substituted. C1-C3 lower alkyl group substituted with an aryl group such as phenyl (eg, benzyl, p-chloro) Benzyl, phenethyl, cyclopentylmethyl, cyclohexylmethyl, etc.),
A lower alkenyl group having 2 to 3 carbon atoms which may be substituted with an aryl group such as cycloalkyl having 3 to 8 carbon atoms or phenyl which may be substituted (eg, vinyl such as cinnamyl, propenyl, allyl, isopropenyl) Such as those having an alkenyl moiety), optionally substituted aryl groups such as phenyl (eg, phenyl, p-tolyl, naphthyl, etc.), straight-chain or branched lower alkoxy groups having 1 to 6 carbon atoms. (Eg methoxy, ethoxy, n
-Propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, etc.), straight-chain or branched lower alkenyloxy having 2 to 8 carbon atoms Group (eg, allyloxy, isobutenyloxy, etc.), cycloalkyloxy group having 3-8 carbon atoms (eg, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, etc.), cycloalkyl having 3-8 carbon atoms (eg, cyclopentyl, cyclohexyl, Cyclohexyl) or a lower alkoxy group having 1 to 3 carbon atoms substituted with an aryl group such as phenyl which may be substituted (eg, benzyloxy, phenethyloxy, cyclopentylmethoxy, cyclohexylmethoxy, and other methoxy,
Ethoxy, n-propoxy, isopropoxy and the like having an alkoxy moiety), cycloalkyl having 3 to 8 carbon atoms (eg, cyclopentyl, cyclohexyl, cycloheptyl, etc.) or an optionally substituted aryl group such as phenyl. A substituted lower alkenyloxy group having 2-3 carbon atoms (eg, those having an alkenyloxy moiety such as vinyloxy such as cinnamyloxy, propenyloxy, allyloxy, isopropenyloxy), an aryloxy group such as optionally substituted phenoxy ( (Eg, phenoxy, p-nitrophenoxy, naphthoxy, etc.)]
And a group represented by] are shown.] And the like. Further, the substituent as R ² is a group capable of forming an anion or a group capable of changing to an anion (eg, alkyl (eg, lower (C _1-4 ) alkyl etc.) or acyl (eg, lower (C _2-5 )). ) Alkanoyl, optionally substituted benzoyl, etc.) may be protected with a tetrazolyl group, a trifluoromethanesulfonic acid amide group, a phosphoric acid group or a sulfonic acid group).

Examples of the substituent R ² are --COOH and salts thereof, --COOMe, --COOEt, --COOtBu, ---.
COOPr, pivaloyloxymethoxycarbonyl, 1
-(Cyclohexyloxycarbonyloxy) ethoxycarbonyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxycarbonyl, acetoxymethoxycarbonyl, propionyloxymethoxycarbonyl, n-butyryloxymethoxycarbonyl, isobutyryl Roxymethoxycarbonyl, (1-ethoxycarbonyloxyethoxy) carbonyl, (1-acetoxyethoxy) carbonyl, (1-isobutyryloxyethoxy) carbonyl, cyclohexylcarbonyloxymethoxycarbonyl, benzoyloxymethoxycarbonyl, cinnamyloxycarbonyl, cyclopentyl Carbonyloxy methoxycarbonyl etc. are mentioned. Further, R ² may be an anion (eg, COO ⁻ , its derivative, etc.) under biological or physiological conditions (for example, in-vivo reaction such as oxidation / reduction or hydrolysis by in-vivo enzyme) or chemically. A group capable of forming) or a group capable of changing into a group. R ² may be a carboxyl group or a prodrug thereof. R ² may be one which can be converted into an anion biologically or chemically in vivo.

Among the above, R ² is carboxyl, esterified carboxyl (eg, methyl ester, ethyl ester or the formula —O—CH (R ⁶ ) —OCO).
(Ester in which the group represented by R ⁵ is bonded to carbonyl), optionally protected tetrazolyl, carboxaldehyde, hydroxymethyl and the like are preferable. In the general formula (I), ring A may have a substituent in addition to the group represented by R ² , for example, halogen (eg, F, C
l, Br, etc.), cyano, nitro, lower (C _1-4 ) alkyl, lower (C _1-4 ) alkoxy, optionally substituted amino group (eg, amino, N-lower (C _1-4 )) Alkylamino (eg, methylamino, etc.), N, N-di-lower (C
_1-4 ) Alkylamino (eg, dimethylamino, etc.), N
-Arylamino (eg, phenylamino, etc.), alicyclic amino (eg, morpholino, piperidino, piperazino, N
-Phenylpiperazino etc.) etc.), formula -CO-D '
[Wherein D'is a hydroxyl group or an alkyl moiety is a hydroxyl group, lower (C _1-4 ) alkoxy, lower (C _2-6 ) alkanoyloxy (eg, acetoxy, pivaloyloxy, etc.) or lower (C _1-6 ) alkoxy group] Rubonyloxy (eg, methoxycarbonyloxy, ethoxycarbonyloxy,
Which may lower substituted with cyclohexyloxycarbonyloxy, etc.) (group represented by C _1-4) an alkoxy] or lower (C _1-4) alkyl or acyl, (e.g., lower (C _2-5) (Alkanoyl, optionally substituted benzoyl, etc.), which may be protected with a tetrazolyl group, a trifluoromethanesulfonic acid amide group, a phosphoric acid group or a sulfonic acid group, and the like, preferably lower (C _1-4 ). Examples include alkyl and halogen. One or two of these substituents may be simultaneously substituted at any position on the ring.

Among the compounds represented by the above formula (I),

[Chemical 13] [In the formula, ring A represents a benzene ring which may further have a substituent in addition to the group represented by R ² , and R ¹ represents hydrogen or an optionally substituted lower (C _1-6 ) alkyl ( Preferably, it is lower (C _1-4 ) alkyl), and Y is —O.
Represents —, —S— or —N (H) —, and R ² is of the formula —CO
-D "[wherein D" is a hydroxyl group or an alkyl moiety is a hydroxyl group, amino, halogen, lower (C _2-6 ) alkanoyloxy (eg, acetyloxy, pivaloyloxy, etc.),
Lower (C _4-7 ) cycloalkanoyloxy, 1-lower (C _1-6 ) alkoxycarbonyloxy (eg, methoxycarbonyloxy, ethoxycarbonyloxy, etc.),
1-lower (C _3-7 ) cycloalkoxycarbonyloxy (eg, cyclohexyloxycarbonyloxy, etc.) or lower (C _1-4 ) alkoxy optionally substituted with lower (C _1-4 ) alkoxy] R ³ represents a group represented by R ³ , and optionally substituted lower (C _1-4 ) alkyl (eg, methyl, triphenylmethyl, methoxymethyl, acetyloxymethyl, methoxycarbonyloxymethyl, ethoxycarbonyloxymethyl). , 1- (cyclohexyloxycarbonyloxy) ethyl, pivaloyloxymethyl and the like) or an acyl group (eg lower (C
_2-5 ) Alkanoyl, benzoyl, etc.), the formula

[Chemical 14] [In formula, i shows -O- or -S-, j is> C =
O,> C = S or> S (O) m, m is a group represented by the above, tetrazolyl or a carboxyl group, and n is 1 or 2] I ') or salts thereof are preferred.

In the formula (I '), the substituent in the optionally substituted lower alkyl of R ¹ is a hydroxyl group,
Examples thereof include an amino group, a halogen or a lower (C _1-4 ) alkoxy group. In the formula (I ′), the substituent other than the group represented by R ² of ring A is halogen (eg, F,
Cl, Br, etc.), lower (C _1-4 ) alkyl, lower (C
_1-4 ) Alkoxy, nitro, formula -CO-D '[wherein
D'is a hydroxyl group or an alkyl moiety having a hydroxyl group, lower (C _1-4 ) alkoxy, lower (C _2-6 ) alkanoyloxy (eg, acetoxy, pivaloyloxy, etc.) or lower (C _1-6 ) alkoxycarbonyloxy (eg, A group represented by lower (C _1-4 ) alkoxy optionally substituted with methoxycarbonyloxy, ethoxycarbonyloxy, cyclohexyloxycarbonyloxy, etc.], or substituted with lower (C _1-4 ) alkyl And amino (preferably lower (C _1-4 ) alkyl, halogen, etc.) may be mentioned, but as the ring A, a benzene ring having no substituent other than the group represented by the formula R ² is used. More preferable.

The above-mentioned salts include pharmaceutically acceptable salts, for example, salts with inorganic bases, salts with organic bases,
Examples thereof include salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like. Preferable examples of the salt with an inorganic base include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and aluminum salt and ammonium salt. Suitable examples of the salt with an organic base include, for example, trimethylamine, triethylamine,
Examples thereof include salts with pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N′-dibenzylethylenediamine and the like. Preferable examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like. Preferable examples of salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p. -Salts with toluenesulfonic acid and the like. Suitable examples of salts with basic amino acids include, for example, salts with arginine, lysine, ornithine, and suitable examples of salts with acidic amino acids include, for example, salts with aspartic acid, glutamic acid, etc. To be

Compounds preferable as the active ingredient of the present invention include JP-A-4-364171 and EP520423.
Examples mentioned in the above are included. General formula (I)
The compounds represented by are disclosed in, for example, JP-A-4-9373, JP-A-4-364171, EP520423 and the like, and can be produced according to the disclosures of these publications.

The compound (I) or its salt having angiotensin II antagonistic activity in the present invention has low toxicity,
Animals, especially mammals (eg humans, dogs, rabbits,
It is used as a medicine for rats, mice, etc., and is used for the prevention or treatment of diabetic nephropathy or glomerulonephritis.
The compound represented by the general formula (I) or a salt thereof can be used orally, parenterally, by inhalation method, rectal injection, or topical administration, and can be used as a pharmaceutical composition or preparation (eg, powder, granules). , Tablets, pills, capsules, injections, syrups, emulsions, elixirs, suspensions, solutions and the like), which are used alone or in combination with at least one compound of the present invention. It can be used as a mixture with a carrier (adjuvant, excipient, excipient and / or diluent, etc.) acceptable as

The pharmaceutical composition can be formulated according to a conventional method. In the present specification, parenteral means
Subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, drip method and the like are included. Injectable preparation, for example
Sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally administrable diluent or solvent, such as an aqueous solution. As the vehicles or solvents that can be used, water,
Examples thereof include Ringer's solution and isotonic saline solution. Further, aseptic non-volatile oil may be used as a solvent or suspending solvent. Any non-volatile oil or fatty acid can be used for this purpose, including natural or synthetic or semi-synthetic fatty oils or fatty acids, and natural or synthetic or semi-synthetic mono-, di- or triglycerides. Suppositories for rectal administration are the drug and suitable non-irritating excipients, such as cocoa butter and polyethylene glycols, which are solid at room temperature but liquid at the temperature of the intestinal tract, which melts in the rectum. It can be manufactured by mixing with a substance that emits.

Examples of solid dosage forms for oral administration include those mentioned above such as powders, granules, tablets, pills and capsules. In such dosage forms, the active ingredient compound is at least one additive, such as sucrose,
Lactose, cellulose sugar, mannitol, maltitol, dextran, starches, agar, alginates, chitins, chitosans, pectins, tragacanth gums, gum arabic, gelatins, collagens, casein, albumin, synthetic or semisynthetic Can be mixed with the polymers or glycerides. Such dosage forms also
As usual, further additives may be included, for example inert diluents, lubricants such as magnesium stearate, parabens, preservatives such as sorbic acid, antioxidants such as ascorbic acid, α-tocopherol, cysteine. Examples include agents, disintegrants, binders, thickeners, buffers, sweeteners, flavoring agents, perfume agents and the like. Tablets and pills can also be manufactured with enteric coating. The liquid formulation for oral administration is
Examples include pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, solutions and the like, which may contain an inert diluent commonly used in the art, such as water.

The dose for a particular patient depends on age, weight,
These factors and other factors are taken into consideration depending on the general health condition, sex, diet, administration time, administration method, excretion rate, drug combination, and the degree of the medical condition being treated by the patient at that time. The compound represented by the general formula (I) or a salt thereof has low toxicity and can be used safely.
The daily dose varies depending on the condition and weight of the patient, the kind of the compound, the administration route, etc., but for example, parenterally subcutaneously, intravenously, intramuscularly or intrarectally, about 0.01
~ 50 mg / person / day, preferably 0.01-20 mg / person / day
Orally administered daily and about 0.01-150 mg / person
It is desirable to administer daily doses, preferably 0.1 to 100 mg / person / day.

[0027]

BEST MODE FOR CARRYING OUT THE INVENTION The present invention is described in more detail below with reference to Examples, but the present invention is not limited thereto. Examples Formulation Example A prophylactic or therapeutic agent for diabetic nephropathy or glomerulonephritis, which comprises the compound (I) or a salt thereof according to the present invention as an active ingredient, can be produced, for example, by the following formulation. 1. Capsule (1) 2-ethoxy-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-7-carboxylic acid 10 mg (2) Lactose 90 mg ( 3) Microcrystalline cellulose 70 mg (4) Magnesium stearate 10 mg 1 capsule 180 mg (1), (2) and 1/2 of (3) and (4) are mixed and then granulated. The rest (4) is added to this and the whole is enclosed in a gelatin capsule. 2. Tablet (1) 2-ethoxy-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-7-carboxylic acid 10 mg (2) Lactose 35 mg (3 ) Corn starch 150 mg (4) Microcrystalline cellulose 30 mg (5) Magnesium stearate 5 mg 1 tablet 230 mg (1) (2), (3), 2/3 of (4) and 1 of (5)
After mixing / 2, granulate. Remaining (4) and (5)
Is added to the granules and pressed into tablets.

3. Injection (1) 2-Methylthio-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-7-carboxylic acid disodium salt 10 mg (2) Inosit 100 mg (3) Benzyl alcohol 20 mg 1 ampoule 130 mg (1), (2) and (3) are dissolved in distilled water for injection so that the total amount becomes 2 ml, and the ampoule is sealed. All steps are performed aseptically. 4. Capsule (1) (±) -1- (cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benz Imidazole-7-carboxylate 10 mg (2) Lactose 90 mg (3) Microcrystalline cellulose 70 mg (4) Magnesium stearate 10 mg 1 capsule 180 mg (1), (2) and (3) and 1/2 of (4) are mixed. Then, granulate. The rest (4) is added to this and the whole is enclosed in a gelatin capsule.

5. Tablet (1) (±) -1- (cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole -7-carboxylate 10 mg (2) Lactose 35 mg (3) Corn starch 150 mg (4) Microcrystalline cellulose 30 mg (5) Magnesium stearate 5 mg 1 tablet 230 mg (1) (2), (3), 2 of 4 / 3 and 1 of (5)
After mixing / 2, granulate. Remaining (4) and (5)
Is added to the granules and pressed into tablets. 6. Injectable (1) 2-ethoxy-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-7-carboxylic acid disodium salt 10 mg (2) Inosit 100 mg (3) Benzyl alcohol 20 mg 1 ampoule 130 mg (1), (2) and (3) are dissolved in distilled water for injection so that the total amount becomes 2 ml, and the ampoule is sealed. All steps are performed aseptically.

7. Capsule (1) 2-butyl-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-7-carboxylic acid 10 mg (2) Lactose 90 mg ( 3) Microcrystalline cellulose 70 mg (4) Magnesium stearate 10 mg 1 capsule 180 mg (1), (2) and 1/2 of (3) and (4) are mixed and then granulated. The rest (4) is added to this and the whole is enclosed in a gelatin capsule. 8. Tablet (1) 2-butyl-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazol-7-carboxylic acid 10 mg (2) Lactose 35 mg (3 ) Corn starch 150 mg (4) Microcrystalline cellulose 30 mg (5) Magnesium stearate 5 mg 1 tablet 230 mg (1) (2), (3), 2/3 of (4) and 1 of (5)
After mixing / 2, granulate. Remaining (4) and (5)
Is added to the granules and pressed into tablets.

9. Capsule (1) Pivaloyloxymethyl 2-butyl-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-7-carboxylate 10 mg ( 2) Lactose 90 mg (3) Microcrystalline cellulose 70 mg (4) Magnesium stearate 10 mg 1 capsule 180 mg (1), (2) and 1/2 of (3) and (4) are mixed and then granulated. The rest (4) is added to this and the whole is enclosed in a gelatin capsule. 10. Tablet (1) Pivaloyloxymethyl 2-ethoxy-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-7-carboxylate 10 mg (2 ) Lactose 35 mg (3) Corn starch 150 mg (4) Microcrystalline cellulose 30 mg (5) Magnesium stearate 5 mg 1 tablet 230 mg (1) 2/3 of (2), (3), (4) and 1 of (5)
After mixing / 2, granulate. Remaining (4) and (5)
Is added to the granules and pressed into tablets.

11. Capsule (1) 2-ethoxy-1-[[2 '-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl]- 1H-Benzimidazole-7-carboxylic acid 10 mg (2) Lactose 90 mg (3) Microcrystalline cellulose 70 mg (4) Magnesium stearate 10 mg 1 capsule 180 mg 1 / of (1), (2) and (3) and (4) Mix 2 and then granulate. The rest (4) is added to this and the whole is enclosed in a gelatin capsule. 12. Tablet (1) 2-ethoxy-1-[[2 '-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl] -1H -Benzimidazole-7-carboxylic acid 10 mg (2) Lactose 35 mg (3) Corn starch 150 mg (4) Microcrystalline cellulose 30 mg (5) Magnesium stearate 5 mg 1 tablet 230 mg (1) (2), (3), (4). 2/3 of 1 and 1 of (5)
After mixing / 2, granulate. Remaining (4) and (5)
Is added to the granules and pressed into tablets.

The biological activity of the compound having angiotensin II antagonism or its salt will be described with reference to test examples. Test Example 1 5/6 Nephrectomized rat (focal glomerulosclerosis model; M
eyer, TW and Renake, HG: Am. J. Physiol.254, F8
56 (1988) or Yoshioka, T., Shiraga, H., Yoshida,
Y., Fogo, A., Glick, AD: J. Clin. Invest. 82, 16
14 (1988)), proteinuria-inhibiting compound 1: (±) -1- (cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2 '-(1
H-tetrazol-5-yl) biphenyl-4-yl]
Methyl] -1H-benzimidazole-7-carboxylate Method: Five-week-old male (Sprague Dawley) rats were anesthetized by intraperitoneal injection of sodium pentobarbital and 2/3 of the right kidney was excised. One week later, the left kidney was completely removed under anesthesia again. After breeding for 2 weeks, urine was collected for 24 hours, and the total amount of urinary protein and the amount of albumin were measured using the A / GB test (Wako Pure Chemical Industries). Using the amount of urinary protein as an index, it was divided into two groups (control group and compound 1 mg / kg / day, po administration group). A group obtained by removing only the left kidney was used as a Sham group.
Compound 1 is a gum arabic / water suspension once daily,
It was orally administered for 8 weeks. 24 at 2, 4, 6, and 8 weeks
Timed urine was collected. Results: Shown in [Table 1]. In the control group, the total amount of urinary protein and albumin increased remarkably from 2 weeks after the operation. On the other hand, no increase in the total urinary protein amount and albumin amount was observed in the Compound 1 administration group, which was significantly lower than that in the control group at 6 to 8 weeks after continuous administration. Compound 1 suppresses protein leakage into urine, and thus is expected to be effective against renal damage in glomerulonephritis and diabetic nephropathy.

[Table 1]

Test Example 2 Type II diabetic rat (Wistar fatty rat; Ikeda, H., Shi
no, A., Matsuo, T., Iwatsuka, H. and Suzuoki,
Z.,: Diabetes, 30, 1045 (1981) or Kava, RA, Wes
t, DB, Lukasik, VA and Greenwood, MRC: Diab
etes, 38, 159 (1989)) proteinuria inhibitory compound 1: (±) -1- (cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2 '-(1
H-tetrazol-5-yl) biphenyl-4-yl]
Methyl] -1H-benzimidazole-7-carboxylate Method: 11-week-old Wistar fatty rats using blood glucose level and urinary protein as an index in 2 groups (control group and 1 mg of compound 1)
/ kg / day, po administration group). A group of non-diabetic control rats (Lean rats) was used. Compound 1 was orally administered once daily as a gum arabic / water suspension,
Urine was collected for 24 hours at 2, 4, 6, 8, and 10 weeks. A part of the 3000 rpm supernatant of urine was collected in a column (Pharma
After desalting with cia PD10), total urinary protein was measured by the Lowry method and urinary albumin was measured by the ELISA method. Results: Shown in [Table 2]. Urine total protein was Lean r in the control group
It increased about 3-fold compared to the at group, but this increase was suppressed by 1.2-1.5 fold by administration of Compound 1. The urinary albumin amount was increased about 100 times in the control group as compared with the Lean rat group, but this increase was 20-30 by administration of Compound 1.
It was suppressed twice. Compound 1 had no effect on the blood glucose level. Compound 1 reduces urinary protein in a non-insulin-dependent diabetes model, and thus is expected to be effective against renal damage in diabetic nephropathy.

[Table 2]

Test Example 3 Acute toxicity test compound 1: (±) -1- (cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2 '-(1
H-tetrazol-5-yl) biphenyl-4-yl]
Methyl] -1H- benzimidazole-7-carboxylate compound 1 of The LD _50, the 4-week-old Jcl: ICR mice (male, female) and 5-week-old Jcl: Wistar rats (male,
In females), the dose is 2000 mg / kg or more after single oral administration.

[0036]

The drug of the present invention can be advantageously used for the prevention or treatment of diabetic nephropathy or glomerulonephritis.

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61P 43/00 116 A61P 43/00 116 C07D 403/10 C07D 403/10 // C07D 413/10 413/10 (72) Inventor Keiji Kubo 4-12-25-202 Hancho, Minoh City, Osaka Prefecture F-term (reference) 4C063 AA01 BB06 CC47 CC58 DD26 EE01 4C086 AA01 AA02 BC62 BC71 GA07 GA09 MA01 MA04 NA14 ZA42 ZA81 ZC17 ZC35

Claims (14)

[Claims] 1. A compound represented by the formula (I ′): (In the formula, R ¹ represents lower (C _1-4 ) alkyl which may be substituted with a substituent selected from a hydroxyl group, an amino group, halogen and a lower (C _1-4 ) alkoxy group, and Y represents —O. Represents-, --S-- or --N (H)-, and R ² is of the formula:
CO-D "[wherein D" is (1) hydroxyl group or (2) alkyl moiety is hydroxyl group, amino, halogen, lower ( _C2-6 )
Alkanoyloxy, lower (C _4-7 ) cycloalkanoyloxy, 1-lower (C _1-6 ) alkoxycarbonyloxy, 1-lower (C _3-7 ) cycloalkoxycarbonyloxy or lower (C _1-4 ) alkoxy represents a group represented by optionally substituted lower (C _{1- 4)} an alkoxy], R ³ is protected, respectively optionally substituted lower (C _1-4) alkyl group or an acyl group May be (1) carboxyl group, (2) tetrazolyl group or (3) formula: [In formula, i shows -O- or -S-, j is> C =
O,> C = S or> S (O) m, m represents 0, 1 or 2, and n represents 0 or 1, or a salt thereof. (However, (±)
-1- (Cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2 '-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H
-A prophylactic or therapeutic agent for diabetic nephropathy or glomerulonephritis, which comprises benzimidazole-7-carboxylate or a salt thereof) as an active ingredient. 2. The agent according to claim 1, wherein R ¹ is ethyl. 3. The agent according to claim 1, wherein R ¹ is ethyl and Y is —O—. 4. The agent according to claim 1, wherein R ² is lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy. 5. R ³ is The agent according to claim 1, which is 6. The agent according to claim 1, wherein R ³ is tetrazolyl. 7. R ³ is 2,5-dihydro-5-oxo-
The agent according to claim 1, which is 1,2,4-oxadiazol-3-yl. 8. R ² is lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy and R 2
The agent according to claim 1, wherein ³ is tetrazolyl. 9. R ¹ is lower alkyl and Y is —O—,
The agent according to claim 1, wherein R ² is lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy, and R ³ is tetrazolyl. 10. A compound represented by the formula (I ′) is 2-ethoxy-1-[[2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazole-. The agent according to claim 1, which is a 7-carboxylic acid or a salt thereof. 11. A compound represented by the formula (I ′) is pivaloyloxymethyl 2-ethoxy-1-[[2 ′-(1H
The agent according to claim 1, which is-tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazol-7-carboxylate or a salt thereof. 12. A compound represented by formula (I ′) is 2-ethoxy-1-[[2 ′-(4,5-dihydro-5-oxo-1,2,4-oxadiazole-3- Il) biphenyl-4-yl] methyl] -1H-benzimidazole-
The agent according to claim 1, which is a 7-carboxylic acid or a salt thereof. 13. 2-Ethoxy-1-[[2 '-(1H-
A preventive or therapeutic agent for glomerulosclerosis, which comprises tetrazol-5-yl) biphenyl-4-yl] methyl] -1H-benzimidazol-7-carvone or a salt thereof as an active ingredient. 14. 2-Ethoxy-1-[[2 '-(4,5
-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl] methyl] -1H
-A preventive or therapeutic agent for glomerulosclerosis, which comprises benzimidazole-7-carboxylic acid or a salt thereof as an active ingredient.